How a patient advocacy group developed the first proposed draft guidance document for industry for submission to the U.S. Food and Drug Administration
Crossref DOI link:
Update policy: https://doi.org/10.1007/SPRINGER_CROSSMARK_POLICY
Bridges, John F. P.
Fallon, Justin R.
Flanigan, Kevin M.
Franson, Timothy R.
Sweeney, H. Lee
unspecified valid from 2015-06-24